-
Signature
-
Michael J. Farrell, Chief Executive Officer
-
Issuer symbol
-
RMD
-
Transactions as of
-
08 Sep 2025
-
Net transactions value
-
-$1,413,556
-
Form type
-
4
-
Filing time
-
09 Sep 2025, 16:10:04 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Farrell Michael J. |
Chief Executive Officer |
RESMED INC., 9001 SPECTRUM CENTER BLVD, SAN DIEGO |
Michael J. Farrell, Chief Executive Officer |
09 Sep 2025 |
0001485164 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
RMD |
ResMed Common Stock |
Options Exercise |
$814,035 |
+8,009 |
+1.7% |
$101.64 |
475,801 |
08 Sep 2025 |
Direct |
F1 |
| transaction |
RMD |
ResMed Common Stock |
Sale |
$2,227,590 |
-8,009 |
-1.7% |
$278.14 |
467,792 |
08 Sep 2025 |
Direct |
F1, F2 |
| holding |
RMD |
ResMed Common Stock |
|
|
|
|
|
2,090 |
08 Sep 2025 |
Lisette and Michael Farrell Family Trust |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
RMD |
ResMed Common Stock Options |
Options Exercise |
$0 |
-8,009 |
-33% |
$0.000000 |
16,020 |
08 Sep 2025 |
ResMed Common Stock |
8,009 |
$101.64 |
Direct |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: